If a proposed Vermont bill is successful, drug companies would have to explain why they hiked prices on certain drugs.
If a proposed Vermont bill is successful, drug companies would have to explain why they hiked prices on certain drugs.
The state Senate passed S.216 – and the House preliminarily approved the bill – which would require the state health board to submit a list of 15 prescription drugs with dramatic price increases to the state attorney general’s office. The drug manufacturers involved would need “to provide justification for the increase in the price of the drug”, according to the bill.
Related: Top 7 new facts about drug spending
However, there are no penalties for drug manufacturers who choose not to comply.
The bill also requires health insurers to make information about their prescription drug formularies available to enrollees, potential enrollees and health care providers via interactive web sites. In addition, hospitals would have to provide prescription drug cost-sharing information to hospital-affiliated physicians through the hospital’s electronic prescribing system.
Related: Hearing ups pressure on drugmakers’ prices
However, Pharmaceutical Research and Manufacturers of America (PhRMA) said that the legislation will increase drug prices. Forcing drug manufacturers to disclose prices would “chill the incentive” for drugmakers to give discounts to certain populations who need discounts, PhRMA wrote in its testimony to the legislature.
“In fact, the Federal Trade Commission has indicated that disclosure of proprietary information would not lead to lower prices, but would likely lead to increased prices,” PhRMA wrote.
In addition, the pricing information might not be relevant because, in many cases, manufacturers “are not privy to the final price paid in Vermont,” PhRMA wrote.
Read more: Americans want drug pricing reform
Next, the bill will go before Gov. Peter Shumlin.
Skyrizi Overtakes Humira in U.S. Sales Numbers
November 8th 2024For the first time, Skyrizi has replaced Humira as AbbVie’s sales driver, largely due to companies encouraging “product hopping” to avoid competition, creating concerns for the sustainability of the burgeoning adalimumab biosimilar market.
Read More
FDA Advisory Committee Votes Down Sotagliflozin in Type 1 Diabetes and CKD
November 1st 2024Committee members said there was uncertainty around sotagliflozin in patients with kidney disease. The FDA is currently reviewing the oral therapy as an adjunct to insulin to help control glycemic levels in adults with type 1 diabetes and chronic kidney disease. The agency’s goal date is Dec. 20, 2024.
Read More